Quantum Private Wealth LLC Sells 93 Shares of DexCom, Inc. (NASDAQ:DXCM)

Quantum Private Wealth LLC lowered its position in shares of DexCom, Inc. (NASDAQ:DXCM) by 1.3% in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 7,009 shares of the medical device company’s stock after selling 93 shares during the period. Quantum Private Wealth LLC’s holdings in DexCom were worth $870,000 at the end of the most recent reporting period.

Several other hedge funds have also recently added to or reduced their stakes in DXCM. Norges Bank bought a new stake in DexCom during the fourth quarter worth about $421,378,000. Winslow Capital Management LLC bought a new stake in DexCom during the third quarter worth about $173,120,000. Vaughan Nelson Investment Management L.P. increased its holdings in shares of DexCom by 16,943.0% in the third quarter. Vaughan Nelson Investment Management L.P. now owns 1,459,730 shares of the medical device company’s stock worth $136,193,000 after buying an additional 1,451,165 shares during the period. 1832 Asset Management L.P. purchased a new position in shares of DexCom in the fourth quarter worth about $151,538,000. Finally, Clearbridge Investments LLC increased its holdings in shares of DexCom by 304.3% in the first quarter. Clearbridge Investments LLC now owns 1,318,079 shares of the medical device company’s stock worth $674,329,000 after buying an additional 992,049 shares during the period. Institutional investors own 97.75% of the company’s stock.

DexCom Stock Down 1.6 %

Shares of DXCM stock traded down $2.25 during midday trading on Wednesday, reaching $134.27. 600,382 shares of the stock were exchanged, compared to its average volume of 2,958,854. DexCom, Inc. has a 1 year low of $74.75 and a 1 year high of $142.00. The company’s 50 day moving average is $129.06 and its two-hundred day moving average is $116.16. The company has a current ratio of 2.84, a quick ratio of 2.48 and a debt-to-equity ratio of 1.18. The firm has a market cap of $51.76 billion, a PE ratio of 104.21, a price-to-earnings-growth ratio of 2.31 and a beta of 1.20.

DexCom (NASDAQ:DXCM) last posted its earnings results on Thursday, February 8th. The medical device company reported $0.50 earnings per share for the quarter, topping analysts’ consensus estimates of $0.43 by $0.07. DexCom had a return on equity of 28.31% and a net margin of 14.95%. The firm had revenue of $1.03 billion for the quarter, compared to the consensus estimate of $1.02 billion. During the same quarter in the prior year, the business earned $0.34 EPS. The business’s revenue for the quarter was up 26.9% on a year-over-year basis. On average, equities research analysts predict that DexCom, Inc. will post 1.76 EPS for the current year.

Insiders Place Their Bets

In other DexCom news, EVP Michael Jon Brown sold 2,624 shares of the company’s stock in a transaction that occurred on Thursday, March 28th. The stock was sold at an average price of $140.04, for a total transaction of $367,464.96. Following the transaction, the executive vice president now owns 68,682 shares in the company, valued at approximately $9,618,227.28. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. In other news, CEO Kevin R. Sayer sold 81,007 shares of the business’s stock in a transaction that occurred on Tuesday, March 12th. The stock was sold at an average price of $133.36, for a total value of $10,803,093.52. Following the sale, the chief executive officer now directly owns 333,526 shares of the company’s stock, valued at approximately $44,479,027.36. The sale was disclosed in a legal filing with the SEC, which is accessible through the SEC website. Also, EVP Michael Jon Brown sold 2,624 shares of the business’s stock in a transaction that occurred on Thursday, March 28th. The stock was sold at an average price of $140.04, for a total value of $367,464.96. Following the completion of the sale, the executive vice president now directly owns 68,682 shares in the company, valued at $9,618,227.28. The disclosure for this sale can be found here. In the last quarter, insiders have sold 187,385 shares of company stock worth $25,256,617. Company insiders own 0.41% of the company’s stock.

Analyst Ratings Changes

Several research analysts have recently commented on the company. UBS Group lifted their price objective on DexCom from $153.00 to $163.00 and gave the stock a “buy” rating in a report on Wednesday, April 10th. Citigroup lifted their price objective on DexCom from $148.00 to $161.00 and gave the stock a “buy” rating in a report on Wednesday, April 3rd. StockNews.com upgraded DexCom from a “hold” rating to a “buy” rating in a report on Wednesday, April 3rd. Royal Bank of Canada assumed coverage on DexCom in a report on Tuesday, March 12th. They issued an “outperform” rating and a $165.00 price objective on the stock. Finally, Piper Sandler lifted their price objective on DexCom from $135.00 to $150.00 and gave the stock an “overweight” rating in a report on Tuesday, December 19th. Two analysts have rated the stock with a hold rating, thirteen have issued a buy rating and one has assigned a strong buy rating to the company’s stock. According to MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus target price of $141.40.

About DexCom

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.